National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

From the 1/7/2022 release of VAERS data:

This is VAERS ID 366696

Government Disclaimer on use of this data



Case Details

VAERS ID: 366696 (history)  
Form: Version 1.0  
Age: 17.0  
Sex: Female  
Location: Foreign  
Vaccinated:2009-10-06
Onset:2009-10-06
   Days after vaccination:0
Submitted: 2009-11-11
   Days after onset:36
Entered: 2009-11-10
   Days after submission:1
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS AHPVA014EA / 2 LA / IM

Administered by: Other       Purchased by: Other
Symptoms: Blood count normal, C-reactive protein increased, Chills, Diarrhoea, Dyspnoea, Headache, Nausea, No reaction on previous exposure to drug, Pyrexia, Retching, Tremor
SMQs:, Anaphylactic reaction (broad), Acute pancreatitis (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Pseudomembranous colitis (broad), Parkinson-like events (broad), Acute central respiratory depression (broad), Pulmonary hypertension (broad), Noninfectious encephalopathy/delirium (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Cardiomyopathy (broad), Noninfectious diarrhoea (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypoglycaemia (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 2 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Blood count, 06Oct2009, normal; C-reactive protein increased, 06Oct2009, 34mg/dl
CDC Split Type: D0063163A

Write-up: This case was reported by a physician and described the occurrence of dyspnea in a 17-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Previous vaccination with the first dose of CERVARIX (GlaxoSmithKline), given on an unspecified date, was well tolerated. on 06 October 2009, the subject received the second dose of CERVARIX (0.5 ml, unknown). Approximately two hours post vaccination with CERVARIX, on 06 October 2009, the subject experienced shaking chills, headache, retching, nausea, diarrhea, fever and dyspnea. The subject experienced no reaction at injection site. The subject was hospitalized by the parents overnight. Blood count was normal. C-reactive protein (CRP) was increased (34 mg/dl). On the next day, on 07 October 2009, all events were resolved. Follow-up information was received on 05 November 2009 from the reporting physician. The subject has no underlying or concurrent medical conditions or other risk factors. The subject received no concomitant medication. Previous vaccination with CERVARIX was well tolerated. On 06 October 2009 the subject received the second dose of CERVARIX (0.5 ml, intramuscular, left deltoid). Approximately two hours post vaccination with CERVARIX, on 06 October 2009 at around 18:00, the subject experienced dyspnea, vomiting, diarrhea, headache and fever. The subject was treated with ibuprofen (Ibu). After about six hours, on 07 October 2009 at around 00:00 (midnight), all events were resolved. The vaccination course with CERVARIX was discontinued. The reporting physician considered that the events were probably related to vaccination with CERVARIX. No further information will be available.


New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=366696


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166